Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Study Completion Date

September 30, 2003

Conditions

Systemic SclerosisScleroderma

Interventions

DRUG

Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody

Trial Locations (4)

University of Texas - Houston Medical School, Houston

UCLA-Department of Medicine, Division of Rheumatology, Los Angeles

Boston Medical Center, Boston

UMDNJ Scleroderma Program, New Brunswick